Læknaneminn

Ataaseq assigiiaat ilaat

Læknaneminn - 01.04.1997, Qupperneq 111

Læknaneminn - 01.04.1997, Qupperneq 111
The drug-AIDS hypothesis * product label of an AZT bottle supplied by Sigma, a non-medical provider of the drug, points out, with skuil and cross bones, AZTs toxicity to the bone mar- row, the very source ofT-cells (Fig. 4). Even the pri- mary provider of AZT, the Glaxo/Burroughs Wellcome company states in the Physicians’Desk Reference that, “It was often difficult to distinguish adverse events possi- bly associated with zidovudine [AZT] administration from underlying signs of HIV disease...” 152. Finaily, the National Institutes of Child Health and Development recently confirmed that, “Zidovudine use is confounded by progression of HIV disease” 205. The inevitable darnage caused by AZT prescriptions is compounded by many of the concomitant medicines taken by most, if not all HlV-positive Americans with AIDS and at risk for AIDS (Table 7). For example, some of the antiviral drugs like ganciclovir and acy- clovir are also DNA chain terminators that are nearly as toxic as AZT 207. As expected they were observed to produce “pancytopenia” 208 by killing hemopoietic cells, and to have “direct [toxic] effects on myeloid and erythroid progenitor cells” l52, 209. Moreover, even American AIDS researchers are concerned that many of the anti-infectives used as anti-HIV/AIDS drugs have “nephrotoxic, cytotoxic, and myelosuppresive [effects], such as amphotericin B, co-trimoxazole, dap- sone, interferon, pentamidine, vincristine, flucytosine, adriamycin, vinblastine, and others [which] could potentially increase the risk of hematologic toxicities in patients being treated with ZDV [AZT]” 209. In other words these drugs are immunosuppressive because they intoxicate and kill immune cells. As yet there are no placebo-controlled human or even animal studies in the literature on the toxic effects of protease inhibitors, although over 60,000 Americans are daily users of the most popular brand 210. However, the popular press acknowledges effects such as “suicidal thoughts, twitching, central nervous disorders ...extreme nausea, hallucinations, intense trembling” after several months on the drug 192. And the HIV/AIDS researcher Jerome Groopman of the Beth Israel Medical Center in Boston informed Newsweek in December 1996 that, “some patients have been ‘show- ing signs of the benefits wearing off’” - an effect that is termed “crashing” by the magazine. Even the surrogate markers of presumed benefits of protease inhibitors, like decreased “viral load” 33,34, l77, are lost over several months as “viral load has shot back up again and no one knows why” 210. 4.4. Conclusions. Although AZT cannot prevent or cure AIDS, and although AZT and the other DNA chain terminators are among the most toxic drugs legally available, and although AZT is already known to cause AIDS diseases and accelerates death on its own, about 200,000 HlV-positive Americans are daily recipients of AZT. Most of these are healthy because there are no more than 50,000 to 75,000 American AIDS patients peryear 3. In addition most, perhaps all American HlV-positives at risk for AIDS also take other “concomitant medications” 209 that have known immunosuppressive and other detrimental effects, such as cortisones, dapsone, pentamidine and others 152,194. Furthermore, most HlV-positive and HlV-negative people at risk for AIDS also consume bewildering com- binations and doses of recreational drugs (see 3.). In other words, most Americans at risk for AIDS and with AIDS are walking pharmacies, consuming excessive doses of toxic recreational and toxic medical drugs. 5. DRUG-AIDS HYP0THESIS Since drugs are the only new health risk of Americans and Europeans since the 1970s, and AIDS is the only new epidemic, it is proposed here that the drug epidemic is the cause of the American and European AIDS epidemic. The hypothesis is: All AIDS diseases in America and Europe that exceed their long-established, normal backgrounds (i.e. >95%) are caused by the long-term consumption of recreational drugs, such as cocaine, heroin, nitrite inhalants, and amphetamines, and by prescription of anti-HIV drugs, such as AlZT. Hemophilia-AIDS, transfusion-AIDS, and the extremely rare AIDS cases ofthe generalpopulation reflect the normal incidence plus the AZT-induced incidence of these diseases under a new name. The rarity of AIDS in the general population is the product of (a) the low-fre- quency of AIDS defining diseases in Americans who do not use drugs or have congenital diseases, and (b) the low incidence of HlV-antibody in only 1 in 300 individuals tested (see 2, Fig. 1). African AIDS is a new name for old diseases caused by malnutrition, parasitic infections andpoor sanitation 11,26. LÆKIMANEMINN 109 1-tbl. 1997, 50. árg.
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140

x

Læknaneminn

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknaneminn
https://timarit.is/publication/1885

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.